Format

Send to

Choose Destination
Stem Cell Res Ther. 2017 Jun 5;8(1):126. doi: 10.1186/s13287-017-0593-3.

Mesenchymal stem cells for treating autoimmune dacryoadenitis.

Author information

1
Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute & Tianjin Medical University School of Optometry and Ophthalmology, No.251 Fukang Road, Nankai District, Tianjin, 300384, People's Republic of China.
2
Tianjin Beichen Hospital, No. 7, Beiyi Road, Beichen District, Tianjin, 300400, China.
3
Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute & Tianjin Medical University School of Optometry and Ophthalmology, No.251 Fukang Road, Nankai District, Tianjin, 300384, People's Republic of China. braveheart0717@sina.com.

Abstract

Autoimmune dacryoadenitis, such as Sjögren syndrome, comprises multifactorial and complex diseases. Inflammation of the lacrimal gland plays a key role in the pathogenesis of diseases. Unfortunately, current treatment strategies, including artificial tears, anti-inflammatory drugs, punctual occlusion, and immunosuppressive drugs, are only palliative, and long-term administration of these strategies is associated with adverse effects that limit their utility. Hence, an effective and safe treatment for autoimmune dacryoadenitis is urgently needed. Mesenchymal stem cells (MSCs) have emerged as a promising tool for treating autoimmune dacryoadenitis, owing to their immunosuppressive properties, tissue repair functions, and powerful differentiation capabilities. A large number of studies have focused on the effect of MSCs on autoimmune diseases, such as autoimmune uveitis, inflammatory bowel disease, and collagen-induced arthritis, but few studies have, to date, unequivocally established the efficacy of MSCs for treating autoimmune dacryoadenitis. In this review, we discuss recent advances in MSC treatment for autoimmune dacryoadenitis.

KEYWORDS:

Autoimmune dacryoadenitis; Immunomodulation; Mesenchymal stem cells

PMID:
28583168
PMCID:
PMC5460436
DOI:
10.1186/s13287-017-0593-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center